Does genotype-guided dosing of warfarin improve the percentage of time in the therapeutic INR range in patients initiating warfarin therapy?
Genotype-guided dosing of warfarin improves the time in therapeutic INR range during therapy initiation compared to standard dosing.
Pharmacogenetic-based dosing was associated with a higher percentage of time in the therapeutic INR range than was standard dosing during the initiation of warfarin therapy. (Funded by the European Commission Seventh Framework Programme and others; ClinicalTrials.gov number, NCT01119300.).
Pirmohamed et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: